PharmaEngine, Inc. (TPEX:4162)
Taiwan · Delayed Price · Currency is TWD 55.60
-0.20 (-0.36%)
Sep 18, 2026, 1:30 PM CST
PharmaEngine Revenue
PharmaEngine had revenue of 258.02M TWD in the quarter ending June 30, 2026, with 31.11% growth. This brings the company's revenue in the last twelve months to 1.03B, down -58.69% year-over-year. In the year 2025, PharmaEngine had annual revenue of 911.42M, down -63.88%.
Revenue (ttm)
1.03B
Revenue Growth
-58.69%
P/S Ratio
7.79
Revenue / Employee
22.78M
Employees
45
Market Cap
7.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 911.42M | -1.61B | -63.88% |
| Dec 31, 2024 | 2.52B | 1.76B | 228.70% |
| Dec 31, 2023 | 767.67M | 113.29M | 17.31% |
| Dec 31, 2022 | 654.38M | -452.00K | -0.07% |
| Dec 31, 2021 | 654.84M | -401.18M | -37.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Adimmune | 1.37B |
| Savior Lifetec | 1.12B |
| TCM Biotech International | 701.63M |
| Tanvex BioPharma | 657.56M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| Polaris Group | 67.95M |
| Locus Cell | 19.40M |